In order to combat the new coronavirus types researchers have discovered that some of these antibodies are particularly efficient.
All identified strains of the virus, including the omicron and delta versions, can be effectively neutralised by antibodies generated from the immune systems of COVID-19 patients who have recovered. The lead investigators of the study were Drs. Natalia Freund, Michael Mor, and Ruofan Lee from the Department of Clinical Microbiology and Immunology at the Sackler Faculty of Medicine.
At the time the initial COVID strain had been successfully treated in Israel, Dr. Freund and her colleagues sequenced every B immune system cell from the patient's blood and found nine antibodies. Several of these antibodies are now capable of neutralising the new coronavirus strains delta and omicron. Two novel antibodies, TAU-2310 and TAU-1109, which link to the increasing viral protein at a different region than where most antibodies have previously concentrated, can neutralise the delta and omicron variants, the research team found. The first antibody, TAU-1109, has a 90% delta strain specificity and a 92% omicron strain specificity. The second antibody, TAU-2310, neutralises 84% of the omicron variant and 97% of the other variants.
Moreover, after three months, the amount of COVID-19 antibodies dramatically drops, which is why people still develop the illness even after taking three doses of the vaccine for reasons that specialists are still trying to fully understand. The researchers believe that tailored antibody therapy and their large-scale distribution to the body can function as an efficient substitute for recurrent boosters, particularly for at-risk populations and people with compromised immune systems. Therefore, it is anticipated that effective antibody therapy will eliminate the need for recurrent booster doses given to the entire population whenever a new variation appears.